Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks

M. S. Turner, D. B. May, R. R. Arthur, Glen Xiong

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.

Original languageEnglish (US)
Pages (from-to)205-213
Number of pages9
JournalJournal of Internal Medicine
Volume261
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Serotonin Uptake Inhibitors
Hemorrhage
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Aspirin
Psychiatry
Exercise

Keywords

  • Adverse drug reaction
  • Bleeding
  • Coagulopathy
  • Platelet
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. / Turner, M. S.; May, D. B.; Arthur, R. R.; Xiong, Glen.

In: Journal of Internal Medicine, Vol. 261, No. 3, 03.2007, p. 205-213.

Research output: Contribution to journalArticle

Turner, M. S. ; May, D. B. ; Arthur, R. R. ; Xiong, Glen. / Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. In: Journal of Internal Medicine. 2007 ; Vol. 261, No. 3. pp. 205-213.
@article{7825c44482bb4ed1942fbb28eaafcfe0,
title = "Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks",
abstract = "The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.",
keywords = "Adverse drug reaction, Bleeding, Coagulopathy, Platelet, Selective serotonin reuptake inhibitor",
author = "Turner, {M. S.} and May, {D. B.} and Arthur, {R. R.} and Glen Xiong",
year = "2007",
month = "3",
doi = "10.1111/j.1365-2796.2006.01720.x",
language = "English (US)",
volume = "261",
pages = "205--213",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks

AU - Turner, M. S.

AU - May, D. B.

AU - Arthur, R. R.

AU - Xiong, Glen

PY - 2007/3

Y1 - 2007/3

N2 - The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.

AB - The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.

KW - Adverse drug reaction

KW - Bleeding

KW - Coagulopathy

KW - Platelet

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33846983203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846983203&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2006.01720.x

DO - 10.1111/j.1365-2796.2006.01720.x

M3 - Article

C2 - 17305643

AN - SCOPUS:33846983203

VL - 261

SP - 205

EP - 213

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 3

ER -